A method of inhibiting the alternative complement pathway activation in a subject mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to properdin and inhibit properdin binding to a complement protein, for example, C5, to inhibit the alternative complement pathway in the subject mammal.